Iris Care Group Midco 2 Limited 15845041 false 2024-07-17 2025-03-31 2025-03-31 2025-03-31 The principal activity of the company is as a holding company. The principal activity of the group is that of the provision of residential care and supported living services for persons with learning disabilities and domiciliary care to the elderly. It is also involved in property development in the care sector. Digita Accounts Production Advanced 6.30.9574.0 true true true false true 15845041 2024-07-17 2025-03-31 15845041 2025-03-31 15845041 bus:Director1 bus:Consolidated 2025-03-31 15845041 bus:Director2 bus:Consolidated 2025-03-31 15845041 bus:Director3 bus:Consolidated 2025-03-31 15845041 bus:Director4 bus:Consolidated 2025-03-31 15845041 bus:Director5 bus:Consolidated 2025-03-31 15845041 bus:OrdinaryShareClass1 bus:Consolidated 2025-03-31 15845041 bus:Consolidated 2025-03-31 15845041 bus:Consolidated 2 2025-03-31 15845041 2 2025-03-31 15845041 core:AcceleratedTaxDepreciationDeferredTax bus:Consolidated 2025-03-31 15845041 core:RevaluationPropertyDeferredTax bus:Consolidated 2025-03-31 15845041 core:TaxLossesCarry-forwardsDeferredTax bus:Consolidated 2025-03-31 15845041 core:FurtherSpecificReserve1ComponentTotalEquity bus:Consolidated 2025-03-31 15845041 core:RetainedEarningsAccumulatedLosses 2025-03-31 15845041 core:RetainedEarningsAccumulatedLosses bus:Consolidated 2025-03-31 15845041 core:ShareCapital 2025-03-31 15845041 core:ShareCapital bus:Consolidated 2025-03-31 15845041 core:TotalEquityAttributableToOwnersParentBeforeNon-controllingInterests bus:Consolidated 2025-03-31 15845041 core:FinanceLeases core:CurrentFinancialInstruments 2025-03-31 15845041 core:FinanceLeases core:CurrentFinancialInstruments bus:Consolidated 2025-03-31 15845041 core:FinanceLeases core:Non-currentFinancialInstruments 2025-03-31 15845041 core:FinanceLeases core:Non-currentFinancialInstruments bus:Consolidated 2025-03-31 15845041 core:HirePurchaseContracts core:CurrentFinancialInstruments 2025-03-31 15845041 core:HirePurchaseContracts core:CurrentFinancialInstruments bus:Consolidated 2025-03-31 15845041 core:HirePurchaseContracts core:Non-currentFinancialInstruments 2025-03-31 15845041 core:HirePurchaseContracts core:Non-currentFinancialInstruments bus:Consolidated 2025-03-31 15845041 core:CurrentFinancialInstruments 2025-03-31 15845041 core:CurrentFinancialInstruments bus:Consolidated 2025-03-31 15845041 core:CurrentFinancialInstruments core:WithinOneYear 2025-03-31 15845041 core:CurrentFinancialInstruments core:WithinOneYear bus:Consolidated 2025-03-31 15845041 core:Non-currentFinancialInstruments 2025-03-31 15845041 core:Non-currentFinancialInstruments bus:Consolidated 2025-03-31 15845041 core:Non-currentFinancialInstruments core:AfterOneYear 2025-03-31 15845041 core:Non-currentFinancialInstruments core:AfterOneYear bus:Consolidated 2025-03-31 15845041 core:DevelopmentCostsCapitalisedDevelopmentExpenditure bus:Consolidated 2025-03-31 15845041 core:Goodwill bus:Consolidated 2025-03-31 15845041 core:PatentsTrademarksLicencesConcessionsSimilar bus:Consolidated 2025-03-31 15845041 core:FurnitureFittingsToolsEquipment bus:Consolidated 2025-03-31 15845041 core:LandBuildings bus:Consolidated 2025-03-31 15845041 core:MotorVehicles bus:Consolidated 2025-03-31 15845041 core:OtherPropertyPlantEquipment bus:Consolidated 2025-03-31 15845041 bus:FRS102 bus:Consolidated 2024-07-17 2025-03-31 15845041 bus:Audited bus:Consolidated 2024-07-17 2025-03-31 15845041 bus:FullAccounts bus:Consolidated 2024-07-17 2025-03-31 15845041 bus:RegisteredOffice bus:Consolidated 2024-07-17 2025-03-31 15845041 bus:Director1 2024-07-17 2025-03-31 15845041 bus:Director1 bus:Consolidated 2024-07-17 2025-03-31 15845041 bus:Director2 bus:Consolidated 2024-07-17 2025-03-31 15845041 bus:Director3 bus:Consolidated 2024-07-17 2025-03-31 15845041 bus:Director4 bus:Consolidated 2024-07-17 2025-03-31 15845041 bus:Director5 bus:Consolidated 2024-07-17 2025-03-31 15845041 bus:HighestPaidDirector bus:Consolidated 2024-07-17 2025-03-31 15845041 bus:OrdinaryShareClass1 bus:Consolidated 2024-07-17 2025-03-31 15845041 bus:Consolidated 2024-07-17 2025-03-31 15845041 bus:Consolidated 1 2024-07-17 2025-03-31 15845041 bus:Consolidated 1 2024-07-17 2025-03-31 15845041 bus:PrivateLimitedCompanyLtd bus:Consolidated 2024-07-17 2025-03-31 15845041 bus:ConsolidatedGroupCompanyAccounts 2024-07-17 2025-03-31 15845041 core:FurtherSpecificReserve1ComponentTotalEquity bus:Consolidated 2024-07-17 2025-03-31 15845041 core:RetainedEarningsAccumulatedLosses 2024-07-17 2025-03-31 15845041 core:RetainedEarningsAccumulatedLosses bus:Consolidated 2024-07-17 2025-03-31 15845041 core:ShareCapital 2024-07-17 2025-03-31 15845041 core:ShareCapital bus:Consolidated 2024-07-17 2025-03-31 15845041 core:TotalEquityAttributableToOwnersParentBeforeNon-controllingInterests bus:Consolidated 2024-07-17 2025-03-31 15845041 core:DevelopmentCostsCapitalisedDevelopmentExpenditure bus:Consolidated 2024-07-17 2025-03-31 15845041 core:Goodwill bus:Consolidated 2024-07-17 2025-03-31 15845041 core:IntangibleAssetsOtherThanGoodwill bus:Consolidated 2024-07-17 2025-03-31 15845041 core:PatentsTrademarksLicencesConcessionsSimilar bus:Consolidated 2024-07-17 2025-03-31 15845041 core:LandBuildingsUnderOperatingLeases bus:Consolidated 2024-07-17 2025-03-31 15845041 core:OtherAssetsUnderOperatingLeases bus:Consolidated 2024-07-17 2025-03-31 15845041 core:PlantEquipmentUnderOperatingLeases bus:Consolidated 2024-07-17 2025-03-31 15845041 core:Buildings bus:Consolidated 2024-07-17 2025-03-31 15845041 core:FurnitureFittingsToolsEquipment bus:Consolidated 2024-07-17 2025-03-31 15845041 core:Land bus:Consolidated 2024-07-17 2025-03-31 15845041 core:LandBuildings bus:Consolidated 2024-07-17 2025-03-31 15845041 core:LeaseholdImprovements bus:Consolidated 2024-07-17 2025-03-31 15845041 core:MotorVehicles bus:Consolidated 2024-07-17 2025-03-31 15845041 core:OtherPropertyPlantEquipment bus:Consolidated 2024-07-17 2025-03-31 15845041 core:KeyManagementPersonnelCloseFamilyMembersEntitiesUnderKeyManagementPersonnelsControl 2024-07-17 2025-03-31 15845041 core:UKTax bus:Consolidated 2024-07-17 2025-03-31 15845041 countries:EnglandWales bus:Consolidated 2024-07-17 2025-03-31 15845041 bus:Consolidated 2024-07-16 15845041 core:FurtherSpecificReserve1ComponentTotalEquity bus:Consolidated 2024-07-16 15845041 core:RetainedEarningsAccumulatedLosses bus:Consolidated 2024-07-16 15845041 core:ShareCapital bus:Consolidated 2024-07-16 15845041 core:TotalEquityAttributableToOwnersParentBeforeNon-controllingInterests bus:Consolidated 2024-07-16 15845041 core:DevelopmentCostsCapitalisedDevelopmentExpenditure bus:Consolidated 2024-07-16 15845041 core:Goodwill bus:Consolidated 2024-07-16 15845041 core:PatentsTrademarksLicencesConcessionsSimilar bus:Consolidated 2024-07-16 15845041 core:FurnitureFittingsToolsEquipment bus:Consolidated 2024-07-16 15845041 core:LandBuildings bus:Consolidated 2024-07-16 15845041 core:MotorVehicles bus:Consolidated 2024-07-16 15845041 core:OtherPropertyPlantEquipment bus:Consolidated 2024-07-16 15845041 2024-07-16 15845041 bus:OrdinaryShareClass1 bus:Consolidated 2024-07-16 15845041 bus:Consolidated 2024-07-16 15845041 bus:Consolidated 2 2024-07-16 15845041 2 2024-07-16 15845041 core:AcceleratedTaxDepreciationDeferredTax bus:Consolidated 2024-07-16 15845041 core:RevaluationPropertyDeferredTax bus:Consolidated 2024-07-16 15845041 core:TaxLossesCarry-forwardsDeferredTax bus:Consolidated 2024-07-16 15845041 core:FinanceLeases core:CurrentFinancialInstruments 2024-07-16 15845041 core:FinanceLeases core:CurrentFinancialInstruments bus:Consolidated 2024-07-16 15845041 core:FinanceLeases core:Non-currentFinancialInstruments 2024-07-16 15845041 core:FinanceLeases core:Non-currentFinancialInstruments bus:Consolidated 2024-07-16 15845041 core:HirePurchaseContracts core:CurrentFinancialInstruments 2024-07-16 15845041 core:HirePurchaseContracts core:CurrentFinancialInstruments bus:Consolidated 2024-07-16 15845041 core:HirePurchaseContracts core:Non-currentFinancialInstruments 2024-07-16 15845041 core:HirePurchaseContracts core:Non-currentFinancialInstruments bus:Consolidated 2024-07-16 15845041 core:CurrentFinancialInstruments 2024-07-16 15845041 core:CurrentFinancialInstruments bus:Consolidated 2024-07-16 15845041 core:CurrentFinancialInstruments core:WithinOneYear 2024-07-16 15845041 core:CurrentFinancialInstruments core:WithinOneYear bus:Consolidated 2024-07-16 15845041 core:Non-currentFinancialInstruments 2024-07-16 15845041 core:Non-currentFinancialInstruments bus:Consolidated 2024-07-16 15845041 core:Non-currentFinancialInstruments core:AfterOneYear 2024-07-16 15845041 core:Non-currentFinancialInstruments core:AfterOneYear bus:Consolidated 2024-07-16 15845041 core:DevelopmentCostsCapitalisedDevelopmentExpenditure bus:Consolidated 2024-07-16 15845041 core:Goodwill bus:Consolidated 2024-07-16 15845041 core:PatentsTrademarksLicencesConcessionsSimilar bus:Consolidated 2024-07-16 15845041 core:FurnitureFittingsToolsEquipment bus:Consolidated 2024-07-16 15845041 core:LandBuildings bus:Consolidated 2024-07-16 15845041 core:MotorVehicles bus:Consolidated 2024-07-16 15845041 core:OtherPropertyPlantEquipment bus:Consolidated 2024-07-16 15845041 bus:HighestPaidDirector bus:Consolidated 2023-07-17 2024-07-16 15845041 bus:Consolidated 2023-07-17 2024-07-16 15845041 core:FurtherSpecificReserve1ComponentTotalEquity bus:Consolidated 2023-07-17 2024-07-16 15845041 core:RetainedEarningsAccumulatedLosses bus:Consolidated 2023-07-17 2024-07-16 15845041 core:ShareCapital bus:Consolidated 2023-07-17 2024-07-16 15845041 core:TotalEquityAttributableToOwnersParentBeforeNon-controllingInterests bus:Consolidated 2023-07-17 2024-07-16 15845041 core:LandBuildingsUnderOperatingLeases bus:Consolidated 2023-07-17 2024-07-16 15845041 core:OtherAssetsUnderOperatingLeases bus:Consolidated 2023-07-17 2024-07-16 15845041 core:PlantEquipmentUnderOperatingLeases bus:Consolidated 2023-07-17 2024-07-16 15845041 core:UKTax bus:Consolidated 2023-07-17 2024-07-16 15845041 bus:Consolidated core:PreviouslyStatedAmount 2023-07-16 15845041 core:FurtherSpecificReserve1ComponentTotalEquity bus:Consolidated core:PreviouslyStatedAmount 2023-07-16 15845041 core:RetainedEarningsAccumulatedLosses bus:Consolidated core:PreviouslyStatedAmount 2023-07-16 15845041 core:ShareCapital bus:Consolidated core:PreviouslyStatedAmount 2023-07-16 15845041 core:TotalEquityAttributableToOwnersParentBeforeNon-controllingInterests bus:Consolidated core:PreviouslyStatedAmount 2023-07-16 iso4217:GBP xbrli:pure xbrli:shares

Registration number: 15845041

Iris Care Group Midco 2 Limited

Annual Report and Consolidated Financial Statements

for the period from 1 May 2024 to 31 March 2025

 

Iris Care Group Midco 2 Limited

Contents

Company Information

1

Strategic Report

2 to 3

Directors' Report

4 to 5

Statement of Directors' Responsibilities

6

Independent Auditor's Report

7 to 9

Consolidated Profit and Loss Account

10

Consolidated Balance Sheet

11

Balance Sheet

12

Consolidated Statement of Changes in Equity

13

Statement of Changes in Equity

14

Notes to the Financial Statements

15 to 28

 

Iris Care Group Midco 2 Limited

Company Information

Directors

A P R Hough

A W Jones

P Kinsey

D R McCartney

T M Power

Registered office

Unit 1 Castleton Court
Fortran Road
St Mellons
Cardiff
Wales
CF3 0LT

Auditors

Hazlewoods LLP
Windsor House
Bayshill Road
Cheltenham
GL50 3AT

 

Iris Care Group Midco 2 Limited

Strategic Report for the period from 1 May 2024 to 31 March 2025

The directors present their strategic report for the period from 1 May 2024 to 31 March 2025. The comparative
period is for the year ended 30 April 2024.

Principal activity

The principal activity of the company is as a holding company.

The principal activity of the group is that of the provision of residential care and supported living services for persons with learning disabilities and domiciliary care to the elderly. It is also involved in property development in the care sector.

Fair review of the business

The results for the year which are set out in the profit and loss account show turnover of £84,002,836 (2024 - £85,339,153) and an operating profit of £8,519,139 (2024 - £7,672,594). At 31 March 2025 the company had net assets of £7,534,544 (2024 - £11,204,266). The directors consider the performance for the year and the financial position at the year end to be satisfactory.

Given the nature of the business, the Group's directors are of the opinion that key performance indicators are important. The Group uses a number of indicators to monitor and improve development, performance or the position of the business. Indicators are reviewed and altered to meet changes both in the internal and external environments. The directors do not consider the inclusion of an analysis using key performance indicators to be necessary to assist users of the financial statements in their understanding of the financial performance or position of the Group.

Environment
The Group is aware of its environmental impact and is monitoring this. There have been some initiatives implemented to aid in decreasing the Group's carbon footprint, measures to minimise waste across the Group where possible, with items being recycled wherever possible and training of managers on environmental awareness.

Energy and carbon reporting
Only two of the Group's subsidiaries are large companies. The energy and carbon reporting for those companies, Ocean Community Services Limited and Beechwood Court Limited can be found in the company's financial statements.

The company has not disclosed information in respect of energy and carbon reporting as its energy consumption is less than 40,000kWh.

Outlook for the business
The Directors expect that the next year will have a mix of challenges as the health and social care industry changes and evolves. However, the Directors believe that the Group is well positioned to manage resultant risk and prosper during the period due to its committed workforce, good working relationships with local authorities in the United Kingdom, strong balance sheet and continued investment in staff development, best practice and modern processes and systems.

 

Iris Care Group Midco 2 Limited

Strategic Report for the period from 1 May 2024 to 31 March 2025

Section 172 statement
The Directors believe that they have effectively implemented their duties under section 172 of the Companies Act 2006. The Company has considered the long term-strategy of the business and consider that this strategy will continue to deliver long term success to the business and it's stakeholders.

The Company is committed to maintaining an excellent reputation and strives to achieve high standards. We are highly selective about the employees that we take on in order to deliver the best value to service users while also maintaining an awareness of the environmental impact of the work done, and strive to reduce carbon footprint where possible.

The Directors recognise the importance of wider stakeholders in delivering their strategy and achieving sustainability within the business. The main stakeholders in the company are considered to be the employees, suppliers and service users.

In ensuring that all stakeholders are considered as part of every decision process, we believe we act fairly between all members of the Company.

Strategy
The Group's primary area of activity was providing care services in residential, nursing and supported living facilities. The Group believes that the key three drivers for its success are the continual focus on the high quality provision of care services, the high level of effort from staff and strong financial control. These drivers support the delivery of the Group's objectives, customer's priorities and future opportunities. This is demonstrated through the successful tender processes being entered into by members of the Group with local authorities.

Principal risks and uncertainties
Principal risks to the organisation are managed through organisation risk registers. These identify all of the potential risks to the business with mitigating controls for managing and monitoring risk.

All risks are profiled, and the Board is regularly updated on the current status of risks to the organisation and commensurate risk mitigation strategies.

Reputational risk
Provision of poor or inappropriate levels of care would cause severe damage to the Group’s brand and the ability of the business to attract new service users. The business operates sophisticated levels of performance monitoring with regular reporting to senior management and the Board of any potential issues.

Health and safety
We believe that no serious injury to staff, residents, their guests or anyone else on our premises is acceptable. Everyone in our business has accountability for health and safety, and they are given the necessary tools (including training, safety equipment and resources) to operate safely.

Government policy
Continued pressure is being exerted on Government and Local Authority spending. The business is mitigating this pressure by concentrating on providing care for those with more complex and challenging behaviour.

Cost base inflation
The principal costs for the successful operation of the business include staff costs, energy and food. All of these areas are subject to on-going cost pressures in excess of inflation. In order to mitigate these issues, the Group has a well organised procurement process to source energy and food at the best possible rates. The Group also has a well organised operations structure to ensure that labour is employed as effectively as possible.
 

Approved by the Board on 27 August 2025 and signed on its behalf by:


A P R Hough
Director

 

Iris Care Group Midco 2 Limited

Directors' Report for the Period from 1 May 2024 to 31 March 2025

The directors present their report and the for the period from 17 July 2024 to 31 March 2025.

Incorporation

The company was incorporated on 17 July 2024.

Directors of the company

The directors who held office during the period were as follows:

A P R Hough (appointed 17 July 2024)

A W Jones (appointed 2 January 2025)

P Kinsey (appointed 17 July 2024)

T M Power (appointed 17 July 2024)

The following director was appointed after the period end:

D R McCartney (appointed 1 April 2025)

Financial instruments

Objectives and policies

The board constantly monitors the group's trading results and revise projections as appropriate to ensure that the group can meet its future obligations as they fall due.

Price risk, credit risk, liquidity risk and cash flow risk

The group is exposed to the usual credit and cash flow risk associated with selling on credit and manages this through credit control procedures. The group's bank loans and loan notes are subject to price and liquidity risk as disclosed in note 17 to the financial statements. The board constantly monitor the company's trading results to ensure that the group can meet its future obligations as they fall due.


Going concern
In assessing the Group's going concern position, the directors have considered the current and forecast trading and financial position of the Group, in addition to the current liquidity and available bank facilities.

During the year the Group made a loss before tax of £1,476,366, however, this includes interest payable to Group companies of £5,515,497. The Group has net assets of £7,534,544, including the loan facility balance.

During the year the Group refinanced replacing the loan facility by £75,750,000, with additional acquisition and revolving facilities totalling £17,000,000 available. The new bank loans are repayable in August 2029. As part of the refinance £11,032,148 of shareholder loan note interest was repaid.

Having reviewed the forecast profits and projected cash flows of the business the directors are confident that the Group will be able to meet its liabilities for the foreseeable future, being a period of at least 12 months from the date of signing of these financial statements. Consequently, the financial statements have been prepared on a going concern basis.

Employment of disabled persons

The group's policy is to recruit disabled workers for those vacancies that they are able to fill. All necessary assistance with initial training courses is given. Once employed, a career plan is developed so as to ensure suitable opportunities for each disabled person. Arrangements are made, wherever possible, for retraining employees who become disabled, to enable them to perform work identified as appropriate to their aptitudes and abilities.

Employee involvement

The group's policy is to recruit disabled workers for those vacancies that they are able to fill. All necessary assistance with initial training courses is given. Once employed, a career plan is developed so as to ensure suitable opportunities for each disabled person. Arrangements are made, wherever possible, for retraining employees who become disabled, to enable them to perform work identified as appropriate to their aptitudes and abilities.

Future developments

The external environment is expected to remain competitive in 2025/26, however the directors remain confident that they will continue to improve the future performance of the business.

 

Iris Care Group Midco 2 Limited

Directors' Report for the Period from 1 May 2024 to 31 March 2025

Important non adjusting events after the financial period

On 9 May 2025, the group acquired 100% of the issued share capital of ALP Supporting Living Services Ltd and purchased the properties for the operation of ALP Supported Living Services Ltd from its previous owners (not within the assets of the company acquired). Total consideration for the two above transactions was £3,474,211 including all fees and deferred consideration.

Disclosure of information to the auditor

Each director has taken the steps that they ought to have taken as a director in order to make themselves aware of any relevant audit information and to establish that the company's auditor is aware of that information. The directors confirm that there is no relevant information that they know of and of which they know the auditor is unaware.

Appointment of auditors

The auditor, Hazlewoods LLP was appointed as auditor to the company, and have expressed their willingness to continue in office.

Approved by the Board on 27 August 2025 and signed on its behalf by:


A P R Hough
Director

 

Iris Care Group Midco 2 Limited

Statement of Directors' Responsibilities

The directors are responsible for preparing the Strategic Report, Directors' Report and the financial statements in accordance with applicable law and regulations.

Company law requires the directors to prepare financial statements for each financial year. Under that law the directors have elected to prepare the financial statements in accordance with United Kingdom Generally Accepted Accounting Practice (United Kingdom Accounting Standards and applicable law). Under company law the directors must not approve the financial statements unless they are satisfied that they give a true and fair view of the state of affairs of the group and company and of the profit or loss of the group for that period. In preparing these financial statements, the directors are required to:

select suitable accounting policies and apply them consistently;

make judgements and accounting estimates that are reasonable and prudent;

state whether applicable UK Accounting Standards have been followed, subject to any material departures disclosed and explained in the financial statements; and

prepare the financial statements on the going concern basis unless it is inappropriate to presume that the company will continue in business.

The directors are responsible for keeping adequate accounting records that are sufficient to show and explain the group's and the company's transactions and disclose with reasonable accuracy at any time the financial position of the group and the company and enable them to ensure that the financial statements comply with the Companies Act 2006. They are also responsible for safeguarding the assets of the group and the company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

 

Iris Care Group Midco 2 Limited

Independent Auditor's Report to the Members of Iris Care Group Midco 2 Limited

Opinion

We have audited the financial statements of Iris Care Group Midco 2 Limited (the 'parent company') and its subsidiaries (the 'group') for the period from 1 May 2024 to 31 March 2025, which comprise the Consolidated Profit and Loss Account, Consolidated Balance Sheet, Balance Sheet, Consolidated Statement of Changes in Equity, Statement of Changes in Equity, and Notes to the Financial Statements, including a summary of significant accounting policies. The financial reporting framework that has been applied in their preparation is applicable law and United Kingdom Accounting Standards, including Financial Reporting Standard 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland' (United Kingdom Generally Accepted Accounting Practice).

In our opinion the financial statements:

give a true and fair view of the state of the group's and the parent company's affairs as at 31 March 2025 and of the group's loss for the period then ended;

have been properly prepared in accordance with United Kingdom Generally Accepted Accounting Practice; and

have been prepared in accordance with the requirements of the Companies Act 2006.

Basis for opinion

We conducted our audit in accordance with International Standards on Auditing (UK) (ISAs (UK)) and applicable law. Our responsibilities under those standards are further described in the auditor responsibilities for the audit of the financial statements section of our report. We are independent of the group in accordance with the ethical requirements that are relevant to our audit of the financial statements in the UK, including the FRC’s Ethical Standard, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Conclusions relating to going concern

In auditing the financial statements, we have concluded that the directors' use of the going concern basis of accounting in the preparation of the financial statements is appropriate.

Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the group's ability to continue as a going concern for a period of at least twelve months from when the original financial statements were authorised for issue.

Our responsibilities and the responsibilities of the directors with respect to going concern are described in the relevant sections of this report.

Other information

The directors are responsible for the other information. The other information comprises the information included in the annual report, other than the financial statements and our auditor’s report thereon. Our opinion on the financial statements does not cover the other information and, except to the extent otherwise explicitly stated in our report, we do not express any form of assurance conclusion thereon.

In connection with our audit of the financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the audit or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether there is a material misstatement in the financial statements or a material misstatement of the other information. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact.

We have nothing to report in this regard.

 

Iris Care Group Midco 2 Limited

Independent Auditor's Report to the Members of Iris Care Group Midco 2 Limited

Opinion on other matter prescribed by the Companies Act 2006

In our opinion, based on the work undertaken in the course of the audit:

the information given in the Strategic Report and Directors' Report for the financial period for which the financial statements are prepared is consistent with the financial statements; and

the Strategic Report and Directors' Report have been prepared in accordance with applicable legal requirements.

Matters on which we are required to report by exception

In the light of our knowledge and understanding of the company and its environment obtained in the course of the audit, we have not identified material misstatements in the Strategic Report and the Directors' Report.

We have nothing to report in respect of the following matters where the Companies Act 2006 requires us to report to you if, in our opinion:

adequate accounting records have not been kept by the parent company, or returns adequate for our audit have not been received from branches not visited by us; or

the parent company financial statements are not in agreement with the accounting records and returns; or

certain disclosures of directors' remuneration specified by law are not made; or

we have not received all the information and explanations we require for our audit.

Responsibilities of directors

As explained more fully in the Statement of Directors' Responsibilities set out on page 6, the directors are responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view, and for such internal control as the directors determine is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, the directors are responsible for assessing the group’s and the parent company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the directors either intend to liquidate the group or the parent company or to cease operations, or have no realistic alternative but to do so.

Auditor’s responsibilities for the audit of the financial statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor’s report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs (UK) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

Extent to which the audit was capable of detecting irregularities, including fraud

Irregularities, including fraud, are instances of non-compliance with laws and regulations. We design procedures in line with our responsibilities, outlined above, to detect material misstatements in respect of irregularities, including fraud. The extent to which our procedures are capable of detecting irregularities, including fraud is detailed below:

We considered the nature of the group’s industry and its control environment and reviewed the groups’s documentation of their policies and procedures relating to fraud and compliance with laws and regulations. We also enquired of management about their own identification and assessment of the risks of irregularities.

We obtained an understanding of the legal and regulatory framework that the group operates in and identified the key laws and regulations that had a direct effect on the determination of material amounts and disclosures in the financial statements, including the UK Companies Act and tax legislation, and, those that do not have a direct effect on the financial statements but compliance with which may be fundamental to the group’s ability to operate or to avoid a material penalty.

We discussed among the audit engagement team regarding the opportunities and incentives that may exist within the organisation for fraud and how and where fraud might occur in the financial statements.

 

Iris Care Group Midco 2 Limited

Independent Auditor's Report to the Members of Iris Care Group Midco 2 Limited

In common with all audits under ISAs (UK), we are also required to perform specific procedures to respond to the risk of management override of controls. In addressing the risk of fraud through management override of controls, we tested the appropriateness of journal entries and other adjustments; assessed whether the judgments made in accounting estimates are indicative of a potential bias; and evaluated the business rationale of any significant transactions that are unusual or outside the normal course of business.

In addition to the above, our procedures to respond to the risks identified included the following:

reviewing financial statement disclosures by testing to supporting documentation to assess compliance with provisions of relevant laws and regulations described as having a direct effect on the financial statements;

performing analytical procedures to identify any unusual or unexpected relationships that may indicate risks of material misstatements due to fraud;

enquiring of management concerning actual and potential litigation and claims and instances of non-compliance with laws and regulations; and

reading minutes of meetings of those charged with governance.

Our audit procedures were designed to respond to risks of material misstatement in the financial statements, recognising that the risk of not detecting a material misstatement due to fraud is higher than the risk of not detecting one resulting from error, as fraud may involve deliberate concealment by, for example, forgery, misrepresentations or through collusion. There are inherent limitations in the audit procedures performed and the further removed non-compliance with laws and regulations is from the events and transactions reflected in the financial statements, the less likely we are to become aware of it.

A further description of our responsibilities is available on the Financial Reporting Council's website at www.frc.org.uk/auditorsresponsibilities. This description forms part of our auditor's report.

Use of our report

This report is made solely to the company’s members, as a body, in accordance with Chapter 3 of Part 16 of the Companies Act 2006. Our audit work has been undertaken so that we might state to the company’s members those matters we are required to state to them in an auditor’s report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the company and the company’s members as a body, for our audit work, for this report, or for the opinions we have formed.





Simon Worsley (Senior Statutory Auditor)
For and on behalf of Hazlewoods LLP, Statutory Auditor

Windsor House
Bayshill Road
Cheltenham
GL50 3AT

27 August 2025

 

Iris Care Group Midco 2 Limited

Consolidated Profit and Loss Account for the Period from 1 May 2024 to 31 March 2025

Note

1 May 2024 to 31 March 2025
£

Year ended 30 April 2024
£

Turnover

3

84,002,836

85,339,153

Cost of sales

 

(59,868,434)

(60,904,555)

Gross profit

 

24,134,402

24,434,598

Administrative expenses

 

(15,615,263)

(16,762,004)

Operating profit

4

8,519,139

7,672,594

Other interest receivable and similar income

6

602,660

-

Interest payable and similar expenses

7

(10,598,165)

(11,970,525)

Loss before tax

 

(1,476,366)

(4,297,931)

Tax on loss

11

(2,193,356)

(841,190)

Loss for the financial period

 

(3,669,722)

(5,139,121)

The above results were derived from continuing operations.

The group has no recognised gains or losses for the period other than the results above.

 

Iris Care Group Midco 2 Limited

(Registration number: 15845041)
Consolidated Balance Sheet as at 31 March 2025

Note

1 May 2024 to 31 March 2025
£

Year ended 30 April 2024
£

Fixed assets

 

Intangible assets

12

18,720,368

21,779,926

Tangible assets

13

133,363,978

128,158,111

 

152,084,346

149,938,037

Current assets

 

Stocks

14

56,520

56,520

Debtors

15

11,403,566

8,077,535

Cash at bank and in hand

 

3,675,031

7,354,793

 

15,135,117

15,488,848

Creditors: Amounts falling due within one year

16

(64,935,338)

(90,571,172)

Net current liabilities

 

(49,800,221)

(75,082,324)

Total assets less current liabilities

 

102,284,125

74,855,713

Creditors: Amounts falling due after more than one year

16

(77,141,192)

(46,659,235)

Provisions for liabilities

11

(17,608,389)

(16,992,212)

Net assets

 

7,534,544

11,204,266

Capital and reserves

 

Called up share capital

19

3

3

Other reserves

32,117,172

32,117,172

Retained earnings

(24,582,631)

(20,912,909)

Equity attributable to owners of the company

 

7,534,544

11,204,266

Shareholders' funds

 

7,534,544

11,204,266

Approved and authorised by the Board on 27 August 2025 and signed on its behalf by:
 

A P R Hough
Director

 

Iris Care Group Midco 2 Limited

(Registration number: 15845041)
Company Balance Sheet as at 31 March 2025

Note

31 March 2025
£

Current assets

 

Debtors

15

128,988,048

Cash at bank and in hand

 

159,724

 

129,147,772

Creditors: Amounts falling due within one year

16

(53,852,937)

Total assets less current liabilities

 

75,294,835

Creditors: Amounts falling due after more than one year

16

(74,459,625)

Net assets

 

835,210

Capital and reserves

 

Called up share capital

19

3

Retained earnings

835,207

Shareholders' funds

 

835,210

The company made a profit after tax for the financial period of £835,207 (2024 - loss of £-).

Approved and authorised by the Board on 27 August 2025 and signed on its behalf by:
 

A P R Hough
Director

 

Iris Care Group Midco 2 Limited

Consolidated Statement of Changes in Equity for the Period from 1 May 2024 to 31 March 2025
Equity attributable to the parent company

Share capital
£

Merger reserve
£

Profit and loss account
£

Total
£

Total equity
£

At 1 May 2024

3

32,117,172

(20,912,909)

11,204,266

11,204,266

Loss for the period

-

-

(3,669,722)

(3,669,722)

(3,669,722)

At 31 March 2025

3

32,117,172

(24,582,631)

7,534,544

7,534,544

Share capital
£

Merger reserve
£

Retained earnings
£

Total
£

Total equity
£

At 1 May 2023

3

-

(15,773,788)

(15,773,785)

(15,773,785)

Loss for the period

-

-

(5,139,121)

(5,139,121)

(5,139,121)

Merger adjustment, increase in equity

-

32,117,172

-

32,117,172

32,117,172

At 30 April 2024

3

32,117,172

(20,912,909)

11,204,266

11,204,266

 

Iris Care Group Midco 2 Limited

Company Statement of Changes in Equity for the Period from 1 May 2024 to 31 March 2025

Share capital
£

Retained earnings
£

Total
£

Profit for the period

-

835,207

835,207

New share capital subscribed

3

-

3

At 31 March 2025

3

835,207

835,210

 

Iris Care Group Midco 2 Limited

Notes to the Financial Statements for the Period from 1 May 2024 to 31 March 2025

 

1

General information

The company is a private company limited by share capital, incorporated in England and Wales.

The address of its registered office is:
Unit 1 Castleton Court
Fortran Road
St Mellons
Cardiff
Wales
CF3 0LT
United Kingdom

 

2

Accounting policies

Summary of significant accounting policies and key accounting estimates

The principal accounting policies applied in the preparation of these financial statements are set out below. These policies have been consistently applied to all the years presented, unless otherwise stated.

Statement of compliance

These financial statements were prepared in accordance with Financial Reporting Standard 102 'The Financial Reporting Standard applicable in the United Kingdom and Republic of Ireland and the Companies Act 2006'.

Basis of preparation

These financial statements have been prepared using the historical cost convention except for, where disclosed in these accounting policies, certain items that are shown at fair value.

The presentational currency of the financial statements is Pounds Sterling, being the functional currency of the primary economic environment in which the company operates. Monetary amounts in these financial statements are rounded to the nearest Pound.

Summary of disclosure exemptions

The company has not presented a cash flow statement on the grounds that the company is a wholly owned subsidiary and a group cash flow statement is included in the financial statements of the ultimate parent company.

Basis of consolidation

The consolidated financial statements consolidate the financial statements of the company and its subsidiary undertakings drawn up to 31 March 2025.

A subsidiary is an entity controlled by the company. Control is achieved where the company has the power to govern the financial and operating policies of an entity so as to obtain benefits from its activities.

The results of subsidiaries acquired or disposed of during the year are included in the Profit and Loss Account from the effective date of acquisition or up to the effective date of disposal, as appropriate. Where necessary, adjustments are made to the financial statements of subsidiaries to bring their accounting policies into line with those used by the group.

The purchase method of accounting is used to account for business combinations that result in the acquisition of subsidiaries by the group. The cost of a business combination is measured as the fair value of the assets given, equity instruments issued and liabilities incurred or assumed at the date of exchange, plus costs directly attributable to the business combination. Identifiable assets acquired and liabilities and contingent liabilities assumed in a business combination are measured initially at their fair values at the acquisition date. Any excess of the cost of the business combination over the acquirer’s interest in the net fair value of the identifiable assets, liabilities and contingent liabilities recognised is recorded as goodwill.

 

Iris Care Group Midco 2 Limited

Notes to the Financial Statements for the Period from 1 May 2024 to 31 March 2025

Inter-company transactions, balances and unrealised gains on transactions between the company and its subsidiaries, which are related parties, are eliminated in full.

Intra-group losses are also eliminated but may indicate an impairment that requires recognition in the consolidated financial statements.

Accounting policies of subsidiaries have been changed where necessary to ensure consistency with the policies adopted by the group. Non-controlling interests in the net assets of consolidated subsidiaries are identified separately from the group’s equity therein. Non-controlling interests consist of the amount of those interests at the date of the original business combination and the non-controlling shareholder’s share of changes in equity since the date of the combination.

Disclosure of long or short period

The financial statements cover a period of 258 days. The accounting period end is in line with that of its ultimate parent undertaking, Iris Care Group Limited.

Going concern

In assessing the Group's going concern position, the directors have considered the current and forecast trading and financial position of the Group, in addition to the current liquidity and available bank facilities.

During the year the Group made a loss before tax of £2,102,935, however, this includes interest payable to Group companies of £7,266,626. The Group has net assets of £6,907,975 at the balance sheet date.

During the year the Group refinanced replacing the loan with a new bank facility of £75,750,000, with additional acquisition and revolving facilities totalling £17,000,000 available. The new bank loans are repayable in August 2029. As part of the refinance £11,032,148 of shareholder loan note interest was repaid.

Having reviewed the forecast profits and projected cash flows of the business the directors are confident that the Group will be able to meet its liabilities for the foreseeable future, being a period of at least 12 months from the date of signing of these financial statements. Consequently, the financial statements have been prepared on a going concern basis.

Changes in accounting policy

The following have been applied for the first time from 1 May 2024 and have had an effect on the financial statements:

Early Adoption of Amendments to FRS102

The company has chosen to early adopt the amendments to FRS 102 issued in September 2024.

The amendments to FRS 102 have revised the accounting for leases which has had the following impact:

Right of use assets as at 31 March 2025 - £1,577,806 (on transition as at 1 May 2024 - £1,758,356)
Lease liabilities as at 31 March 2025 - £1,631,326 (on transition as at 1 May 2024 - £1,758,356)
Impact of profit and loss account for the period 1 May 2024 to 31 March 2025 - loss of £53,520.

The amendments to FRS 102 have introduced changes to revenue recognition policies and fair value measurement requirements. The company has early adopted these amendments with them having no impact on the financial statements.

Judgements

These financial statements do not contain any significant judgements or estimation uncertainty.

Revenue recognition

Turnover comprises the fair value of the consideration received or receivable for the provision of services in the ordinary course of the group’s activities. Turnover is shown net of sales/value added tax, returns, rebates and discounts and after eliminating sales within the company. The group recognises revenue when the amount of revenue can be reliably measured, it is probable that future economic benefits will flow to the entity and specific criteria have been met for each of the group's activities.

Tax

The tax expense for the period comprises current and deferred tax. Tax is recognised in the profit and loss account, except that a charge attributable to an item of income or expense recognised as other comprehensive income is also recognised directly in other comprehensive income.

 

Iris Care Group Midco 2 Limited

Notes to the Financial Statements for the Period from 1 May 2024 to 31 March 2025

The current income tax charge is calculated on the basis of tax rates and laws that have been enacted or substantively enacted by the reporting date in the countries where the group operates and generates taxable income.

Deferred income tax is recognised on temporary differences arising between the tax bases of assets and liabilities and their carrying amounts in the consolidated financial statements and on unused tax losses or tax credits in the group. Deferred income tax is determined using tax rates and laws that have been enacted or substantively enacted by the reporting date.

The carrying amount of deferred tax assets are reviewed at each reporting date and a valuation allowance is set up against deferred tax assets so that the net carrying amount equals the highest amount that is more likely than not to be recovered based on current or future taxable profit.

Tangible assets

Tangible assets are stated in the statement of financial position at cost, less any subsequent accumulated depreciation and subsequent accumulated impairment losses.

The cost of tangible assets includes directly attributable incremental costs incurred in their acquisition and installation.

Depreciation

Depreciation is charged so as to write off the cost of assets, other than land and properties under construction over their estimated useful lives, as follows:

Asset class

Depreciation method and rate

Freehold Property

Nil and 1% on cost

Leasehold land and buildings

Over the term of the lease

Furniture, fittings and equipment

15% reducing balance and 33% on cost

Motor vehicles

25% reducing balance

Freehold land

Nil

Freehold land and buildings in some sub-groups are not depreciated. The directors consider this to be appropriate on the basis that the residual values of the properties are not materially different to their carrying values and therefore any depreciation would be immaterial.

Business combinations

Business combinations are accounted for using the purchase method. The consideration for each acquisition is measured at the aggregate of the fair values at acquisition date of assets given, liabilities incurred or assumed, and equity instruments issued by the group in exchange for control of the acquired, plus any costs directly attributable to the business combination. When a business combination agreement provides for an adjustment to the cost of the combination contingent on future events, the group includes the estimated amount of that adjustment in the cost of the combination at the acquisition date if the adjustment is probable and can be measured reliably.

Intangible assets

Goodwill arising on the acquisition of an entity represents the excess of the cost of acquisition over the group’s interest in the net fair value of the identifiable assets, liabilities and contingent liabilities of the entity recognised at the date of acquisition. Goodwill is initially recognised as an asset at cost and is subsequently measured at cost less accumulated amortisation and accumulated impairment losses. Goodwill is held in the currency of the acquired entity and revalued to the closing rate at each reporting period date.

Negative goodwill arising on an acquisition is recognised on the face of the balance sheet on the acquisition date and subsequently the excess up to the fair value of non-monetary assets acquired is recognised in profit or loss in the periods in which the non-monetary assets are recovered.

Separately acquired trademarks and licences are shown at historical cost.

Trademarks, licences (including software) and customer-related intangible assets acquired in a business combination are recognised at fair value at the acquisition date.

Trademarks, licences and customer-related intangible assets have a finite useful life and are carried at cost less accumulated amortisation and any accumulated impairment losses.

 

Iris Care Group Midco 2 Limited

Notes to the Financial Statements for the Period from 1 May 2024 to 31 March 2025

Amortisation

Amortisation is provided on intangible assets so as to write off the cost, less any estimated residual value, over their useful life as follows:

Asset class

Amortisation method and rate

Goodwill

10% on cost

Software costs

25% on cost

Investments

Investments in equity shares which are publicly traded or where the fair value can be measured reliably are initially measured at fair value, with changes in fair value recognised in profit or loss. Investments in equity shares which are not publicly traded and where fair value cannot be measured reliably are measured at cost less impairment.

Interest income on debt securities, where applicable, is recognised in income using the effective interest method. Dividends on equity securities are recognised in income when receivable.

Cash and cash equivalents

Cash and cash equivalents comprise cash on hand and call deposits, and other short-term highly liquid investments that are readily convertible to a known amount of cash and are subject to an insignificant risk of change in value.

Trade debtors

Trade debtors are amounts due from customers for merchandise sold or services performed in the ordinary course of business.

Trade debtors are recognised initially at the transaction price. All trade debtors are repayable within one year and hence are included at the undiscounted cost of cash expected to be received. A provision for the impairment of trade debtors is established when there is objective evidence that the group will not be able to collect all amounts due according to the original terms of the debtors.

Stocks

Stocks are stated at the lower of cost and estimated selling price less costs to complete and sell. Cost is determined using the first-in, first-out (FIFO) method.

Trade creditors

Trade creditors are obligations to pay for goods or services that have been acquired in the ordinary course of business from suppliers. Accounts payable are classified as current liabilities if the group does not have an unconditional right, at the end of the reporting period, to defer settlement of the creditor for at least twelve months after the reporting date. If there is an unconditional right to defer settlement for at least twelve months after the reporting date, they are presented as non-current liabilities.

Trade creditors are recognised initially at the transaction price and all are repayable within one year and hence are included at the undiscounted amount of cash expected to be paid.

Borrowings

Interest-bearing borrowings are initially recorded at fair value, net of transaction costs. Interest-bearing borrowings are subsequently carried at amortised cost, with the difference between the proceeds, net of transaction costs, and the amount due on redemption being recognised as a charge to the profit and loss account over the period of the relevant borrowing.

Interest expense is recognised on the basis of the effective interest method and is included in interest payable and similar charges.

Borrowings are classified as current liabilities unless the group has an unconditional right to defer settlement of the liability for at least twelve months after the reporting date.

 

Iris Care Group Midco 2 Limited

Notes to the Financial Statements for the Period from 1 May 2024 to 31 March 2025

Leases

Leases in which substantially all the risks and rewards of ownership are retained by the lessor are classified as operating leases. Assets held under operating leases are recognised as right of use assets. These assets are depreciated on a straight - line basis over the lease term. The corresponding liability is included in the Balance sheet as a lease liability.

Leases are classified as finance leases whenever the terms of the lease transfer substantially all the risks and rewards of ownership to the lessee.

Assets held under finance leases are recognised at the lower of their fair value at inception of the lease and the present value of the minimum lease payments. These assets are depreciated on a straight-line basis over the shorter of the useful life of the asset and the lease term. The corresponding liability to the lessor is included in the Balance Sheet as a finance lease obligation.

Lease payments are apportioned between finance costs in the Profit and Loss Account and reduction of the lease obligation so as to achieve a constant periodic rate of interest on the remaining balance of the liability.

Share capital

Ordinary shares are classified as equity. Equity instruments are measured at the fair value of the cash or other resources received or receivable, net of the direct costs of issuing the equity instruments. If payment is deferred and the time value of money is material, the initial measurement is on a present value basis.

Dividends

Dividend distribution to the group’s shareholders is recognised as a liability in the financial statements in the reporting period in which the dividends are declared.

Defined contribution pension obligation

A defined contribution plan is a pension plan under which fixed contributions are paid into a pension fund and the group has no legal or constructive obligation to pay further contributions even if the fund does not hold sufficient assets to pay all employees the benefits relating to employee service in the current and prior periods.

Contributions to defined contribution plans are recognised as employee benefit expense when they are due. If contribution payments exceed the contribution due for service, the excess is recognised as a prepayment.

 

Iris Care Group Midco 2 Limited

Notes to the Financial Statements for the Period from 1 May 2024 to 31 March 2025

Financial instruments


Classification
Financial instruments are classified and accounted for according to the substance of the contractual arrangement, as financial assets, financial liabilities or equity instruments. An equity instrument is any contract that evidences a residual interest in the assets of the company after deducting all of its liabilities. Where shares are issued, any component that creates a financial liability of the company is presented as a liability on the balance sheet. The corresponding dividends relating to the liability component are charged as interest expenses in the profit and loss account.

 Recognition and measurement
All financial assets and liabilities are initially measured at transaction price (including transaction costs), except for those financial assets classified as at fair value through profit or loss, which are initially measured at fair value (which is normally the transaction price excluding transaction costs), unless the arrangement constitutes a financing transaction. If an arrangement constitutes a financing transaction, the financial asset or financial liability is measured at the present value of the future payments discounted at a market rate of interest for a similar debt instrument.

 Impairment
Assets, other than those measured at fair value, are assessed for indicators of impairment at each balance sheet date. If there is objective evidence of impairment, an impairment loss is recognised in profit or loss as described below.

A non financial asset is impaired where there is objective evidence that, as a result of one or more events that occurred after initial recognition, the estimated recoverable value of the asset has been reduced. The recoverable amount of an asset is the higher of its fair value less costs to sell and its value in use.

The recoverable amount of goodwill is derived from measurement of the present value of the future cash flows of the cash-generating units ('CGUs') of which the goodwill is a part. Any impairment loss in respect of a CGU is allocated first to the goodwill attached to that CGU, and then to other assets within that CGU on a pro-rata basis.

Where indicators exist for a decrease in impairment loss, the prior impairment loss is tested to determine reversal. An impairment loss is reversed on an individual impaired asset to the extent that the revised recoverable value does not lead to a revised carrying amount higher than the carrying value had no impairment been recognised. Where a reversal of impairment occurs in respect of a CGU, the reversal is applied first to the assets (other than goodwill) of the CGU on a pro-rata basis and then to any goodwill allocated to that CGU.

For financial assets carried at amortised cost, the amount of an impairment is the difference between the asset’s carrying amount and the present value of estimated future cash flows, discounted at the financial asset’s original effective interest rate.

For financial assets carried at cost less impairment, the impairment loss is the difference between the asset’s carrying amount and the best estimate of the amount that would be received for the asset if it were to be sold at the reporting date.

Where indicators exist for a decrease in impairment loss, and the decrease can be related objectively to an event occurring after the impairment was recognised, the prior impairment loss is tested to determine reversal. An impairment loss is reversed on an individual impaired financial asset to the extent that the revised recoverable value does not lead to a revised carrying amount higher than the carrying value had no impairment been recognised.

 

Iris Care Group Midco 2 Limited

Notes to the Financial Statements for the Period from 1 May 2024 to 31 March 2025

 

3

Turnover

The total turnover of the company has been derived from its principal activity wholly undertaken in the United Kingdom.

 

4

Operating profit

Arrived at after charging/(crediting)

1 May 2024 to 31 March 2025
£

Year ended 30 April 2024
£

Depreciation expense

1,815,059

1,778,284

Amortisation expense

3,249,201

3,274,232

Operating lease expense - property

-

631,229

Operating lease expense - plant and machinery

-

116,228

Operating lease expense - other

-

3,789

Profit on disposal of tangible fixed assets

(186,313)

(78,281)

 

5

Exceptional items

1 May 2024 to 31 March 2025
 £

Year ended 30 April 2024
£

Exceptional expenses

342,882

719,906

Exceptional items in the current period and previous year relate to non-recurring staff costs, and legal and professional fees, off-set by profits on disposal of fixed assets.

 

6

Other interest receivable and similar income

1 May 2024 to 31 March 2025
£

Year ended 30 April 2024
£

Bank interest received

15

-

Net changes in fair value of financial instrument

602,645

-

602,660

-

 

7

Interest payable and similar expenses

1 May 2024 to 31 March 2025
£

Year ended 30 April 2024
£

Interest on bank overdrafts and borrowings

4,137,879

4,028,918

Interest on obligations under finance leases and hire purchase contracts

130,915

7,149

Finance charges adjacent to interest

813,874

167,832

Interest payable on loans from group undertakings

5,515,497

7,766,626

10,598,165

11,970,525

 

Iris Care Group Midco 2 Limited

Notes to the Financial Statements for the Period from 1 May 2024 to 31 March 2025

 

8

Staff costs

The aggregate payroll costs (including directors' remuneration) were as follows:

1 May 2024 to 31 March 2025
£

Year ended 30 April 2024
£

Wages and salaries

46,752,261

45,943,525

Social security costs

4,529,125

4,152,105

Pension costs, defined contribution scheme

867,841

818,316

52,149,227

50,913,946

 

Staff numbers

The average number of persons employed by the company (including directors) during the period, was as follows:

1 May 2024 to 31 March 2025
 No.

Year ended 30 April 2024
 No.

Administration and support

436

367

Sales

1,331

1,346

1,767

1,713


 

Company
The company incurred no staff costs and had no employees other than the directors.

 

9

Directors' remuneration

The directors' remuneration for the period was as follows:

1 May 2024 to 31 March 2025
£

Year ended 30 April 2024
£

Remuneration

204,142

-

Contributions paid to money purchase schemes

1,800

-

205,942

-

During the period the number of directors who were receiving benefits and share incentives was as follows:

2025
No.

2024
No.

Accruing benefits under money purchase pension scheme

1

-

In respect of the highest paid director:

2025
£

2024
£

Remuneration

133,642

-

 

Iris Care Group Midco 2 Limited

Notes to the Financial Statements for the Period from 1 May 2024 to 31 March 2025

 

10

Auditors' remuneration

1 May 2024 to 31 March 2025
£

Year ended 30 April 2024
£

Audit of these financial statements

800

-

Other fees to auditors

Audit-related assurance services

60,500

62,500

All other non-audit services

49,550

50,500

110,050

113,000


 

 

11

Taxation

Tax charged/(credited) in the consolidated profit and loss account

1 May 2024 to 31 March 2025
£

Year ended 30 April 2024
£

Current taxation

UK corporation tax

1,111,986

192,747

UK corporation tax adjustment to prior periods

465,193

209,831

1,577,179

402,578

Deferred taxation

Arising from origination and reversal of timing differences

616,177

438,612

Tax expense in the income statement

2,193,356

841,190

The tax on profit before tax for the period is higher than the standard rate of corporation tax in the UK (2024 - higher than the standard rate of corporation tax in the UK) of 25% (2024 - 25%).

The differences are reconciled below:

1 May 2024 to 31 March 2025
£

Year ended 30 April 2024
£

Loss before tax

(1,476,366)

(4,297,931)

Corporation tax at standard rate

(369,092)

(1,074,483)

Increase in UK and foreign current tax from adjustment for prior periods

465,193

209,831

Tax increase from effect of capital allowances and depreciation

402,626

32,224

Effect of revenues exempt from taxation

(156,642)

-

Effect of expense not deductible in determining taxable profit (tax loss)

1,989,802

3,059,550

Effect of tax losses

(151,550)

(1,385,932)

Tax increase arising from group relief

11,528

-

Deferred tax expense from unrecognised temporary difference from a prior period

1,491

-

Total tax charge

2,193,356

841,190

 

Iris Care Group Midco 2 Limited

Notes to the Financial Statements for the Period from 1 May 2024 to 31 March 2025

Deferred tax

Group

Deferred tax assets and liabilities

31 March 2025

Liability
£

Differences between accumulated depreciation and amortisation and capital allowances

4,941,423

Long term timing differences on fair value uplift of freehold property

12,768,007

Tax losses carried forward

(101,041)

17,608,389

30 April 2024

Liability
£

Differences between accumulated depreciation and amortisation and capital allowances

4,522,289

Long term timing differences on fair value uplift of freehold property

12,768,006

Tax losses carried forward

(298,083)

16,992,212

 

12

Intangible assets

Group

Goodwill
 £

Trademarks, patents and licenses
 £

Internally generated software development costs
 £

Total
£

Cost or valuation

At 1 May 2024

31,425,360

468,075

385,807

32,279,242

Additions acquired separately

-

156,871

32,772

189,643

At 31 March 2025

31,425,360

624,946

418,579

32,468,885

Amortisation

At 1 May 2024

10,318,372

52,504

128,440

10,499,316

Amortisation charge

3,142,536

69,349

37,316

3,249,201

At 31 March 2025

13,460,908

121,853

165,756

13,748,517

Carrying amount

At 31 March 2025

17,964,452

503,093

252,823

18,720,368

At 30 April 2024

21,106,988

415,571

257,367

21,779,926

 

Iris Care Group Midco 2 Limited

Notes to the Financial Statements for the Period from 1 May 2024 to 31 March 2025

 

13

Tangible assets

Group

Land and buildings
£

Furniture, fittings and equipment
 £

Motor vehicles
 £

Right of use assets
£

Total
£

Cost or valuation

At 1 May 2024

127,775,528

7,293,049

562,042

-

135,630,619

Additions

3,535,947

1,991,183

255,662

1,758,356

7,541,148

Disposals

(586,627)

-

(52,840)

-

(639,467)

At 31 March 2025

130,724,848

9,284,232

764,864

1,758,356

142,532,300

Depreciation

At 1 May 2024

4,129,912

3,186,028

156,568

-

7,472,508

Charge for the period

330,799

1,150,542

153,168

180,550

1,815,059

Eliminated on disposal

(69,231)

-

(50,014)

-

(119,245)

At 31 March 2025

4,391,480

4,336,570

259,722

180,550

9,168,322

Carrying amount

At 31 March 2025

126,333,368

4,947,662

505,142

1,577,806

133,363,978

At 30 April 2024

123,645,616

4,107,021

405,474

-

128,158,111

Included within the net book value of land and buildings above is £126,333,368 (2024 - £123,645,616) in respect of freehold land and buildings.
 

The amendments to FRS 102 have revised the accounting for leases. The company has early adopted these amendments, leading to the recognition of right of use assets with a net book value of £1,758,356 on transition as at 1 May 2024 and subsequently £1,577,806 as at 31 March 2025. Right of use assets relate entirely to leasehold properties which the company leases for use in its operations. See note 2 for more details.

Hire purchase agreements
Included within the net book value is £63,230 (2024 - £85,322) relating to assets held under hire purchase agreements. The depreciation charge to the financial statements in the year in respect of such assets amounted to £28,440 (2024 - £32,642).

 

Iris Care Group Midco 2 Limited

Notes to the Financial Statements for the Period from 1 May 2024 to 31 March 2025

 

14

Stocks

 

Group

Company

31 March 2025
£

30 April 2024
£

31 March 2025
£

30 April 2024
£

Raw materials and consumables

56,520

56,520

-

-

 

15

Debtors

   

Group

Company

Note

31 March 2025
£

30 April 2024
£

31 March 2025
£

30 April 2024
£

Trade debtors

 

6,899,333

6,429,142

-

-

Amounts owed by group undertakings

20

1,328,529

-

128,385,400

-

Other debtors

 

634,654

50,085

3

-

Prepayments

 

1,894,684

1,598,308

-

-

Corporation tax asset

11

43,721

-

-

-

Derivative financial instruments

 

602,645

-

602,645

-

 

11,403,566

8,077,535

128,988,048

-

 

16

Creditors

   

Group

Company

Note

31 March 2025
£

30 April 2024
£

31 March 2025
£

30 April 2024
£

Due within one year

 

Loans and borrowings

17

422,247

1,342,331

-

-

Trade creditors

 

2,838,154

2,725,028

-

-

Amounts due to group undertakings

20

53,964,685

78,648,079

53,852,937

-

Social security and other taxes

 

1,495,298

1,371,715

-

-

Outstanding defined contribution pension costs

 

290,528

417,191

-

-

Other payables

 

1,939,185

1,231,258

-

-

Accruals

 

2,074,284

2,287,799

-

-

Corporation tax liability

11

-

1,123,535

-

-

Deferred income

 

1,910,957

1,424,236

-

-

 

64,935,338

90,571,172

53,852,937

-

Due after one year

 

Loans and borrowings

17

74,459,625

44,691,845

74,459,625

-

Other non-current financial liabilities

 

1,428,575

1,923,553

-

-

HP and finance lease liabilities

17

1,252,992

43,837

-

-

 

77,141,192

46,659,235

74,459,625

-

Other creditors due in more than one year consist of deferred consideration.

 

Iris Care Group Midco 2 Limited

Notes to the Financial Statements for the Period from 1 May 2024 to 31 March 2025

 

17

Loans and borrowings

Current loans and borrowings

 

Group

Company

31 March 2025
£

30 April 2024
£

31 March 2025
£

30 April 2024
£

Bank borrowings

-

1,312,125

-

-

Hire purchase contracts

30,043

30,206

-

-

Lease liabilities

392,204

-

-

-

422,247

1,342,331

-

-

Non-current loans and borrowings

 

Group

Company

31 March 2025
£

30 April 2024
£

31 March 2025
£

30 April 2024
£

Bank borrowings

74,459,625

44,691,845

74,459,625

-

Hire purchase contracts

13,871

43,837

-

-

Lease liabilities

1,239,121

-

-

-

75,712,617

44,735,682

74,459,625

-

The bank loan commenced on 23 September 2024 with a final repayment date of 25 September 2029. The rate of interest is 3.695% above the margin rate 3.15% between 25 September 2024 and 29 September 2028, whereby the bank have agreed a fixed rate of interest. The bank loan is shown net of debt costs £1,290,375. The gross amount outstanding as at 31 March 2025 is £74,459,625.

Hire purchase liabilities are secured against the assets to which they relate.

The amendments to FRS 102 have revised the accounting for leases. The company has early adopted these amendments, leading to the recognition of lease liabilities with a carrying value of £1,758,356 on transition as at 1 May 2024 and subsequently £1,631,326 as at 31 March 2025. Interest of £124,363 has been recognised for the period 1 May 2024 to 31 March 2025 using an interest rate of 7.6% with a cash outflow for the same period of £251,393. A lease liability of £392,204 is due within one year and £1,239,121 is due within 1-5 years. See note 2 for more details.

 

Iris Care Group Midco 2 Limited

Notes to the Financial Statements for the Period from 1 May 2024 to 31 March 2025

 

18

Pension and other schemes

Defined contribution pension scheme

The group operates a defined contribution pension scheme. The pension cost charge for the period represents contributions payable by the group to the scheme and amounted to £867,841 (2024 - £818,316).

Contributions totalling £290,528 (2024 - £417,191) were payable to the scheme at the end of the period and are included in creditors.

 

19

Share capital

Allotted, called up and fully paid shares

31 March 2025

30 April 2024

No.

£

No.

£

Ordinary of £0.01 each

300

3

300

3

       
 

20

Related party transactions

Company

Summary of transactions with key management

Key management personnel are considered to be the directors of the company and key management personnel compensation is disclosed in note 9 to the financial statements.
 

 

21

Non adjusting events after the financial period

On 9 May 2025, the group acquired 100% of the issued share capital of ALP Supporting Living Services Ltd and purchased the properties for the operation of ALP Supported Living Services Ltd from its previous owners (not within the assets of the company acquired). Total consideration for the two above transactions was £3,474,211 including all fees and deferred consideration.

 

22

Parent and ultimate parent undertaking

The company's immediate parent is Iris Care Group Midco Limted, incorporated in England and Wales.

 The ultimate parent is Iris Care Group Limted, incorporated in England and Wales.

 The ultimate controlling party is funds managed by Ancala Partners LLP, a limited liability partnership registered in England and Wales.